Sanofi (SNY-2%) and Regeneron (REGN-2.5%) today announce that they are enrolling patients in more than 10 late-stage clinical trials , named Odyssey, for a potentially first-in-class cholesterol - lowering drug targeting an enzyme called PCSK9. Odyssey will involve more than 22K patients, including 18K in a trial to measure cardiovascular outcomes such as heart attacks and strokes.